
InfusionReady
IV compatibility & line plan
About
What's New in InfusionReady
1.0.6 (7)
July 11, 2026
The infusion catalog now covers 199 continuous IV infusions, adding newer and higher-acuity agents across antimicrobials (e.g., cefiderocol, meropenem-vaborbactam, aztreonam-avibactam, rezafungin, isavuconazole, dalbavancin, oritavancin), antidotes and reversal agents (idarucizumab, andexanet, digoxin immune Fab, dantrolene, pralidoxime, physostigmine), and additional cardiac, sedation, and critical-care drips. Every infusion and every Y-site verdict now shows its cited medical sources, with tappable links to the underlying references (Trissel's, King Guide, Micromedex) and, for newer agents, FDA prescribing information via DailyMed. Added documented Y-site incompatibilities for several new agents — including aminoglycoside-inactivating β-lactams, D5W-only lipoglycopeptides that precipitate in saline, and foscarnet with calcium-containing solutions. The conservative safety model is unchanged: infusions are only grouped when documented compatible, dedicated-line drugs are always isolated, and anything without reliable data stays on a separate line.
More



